Purchase strengthens BioTrove’s IP position in through-hole array technology

Woburn, MA, September 26, 2003—BioTrove, Inc. today announced the purchase of an intellectual property portfolio covering through-hole array technology from Genencor International Inc. (GCOR). The portfolio includes several issued patents and multiple patent filings in the United States and overseas. The issued and pending claims augments and strengthens BioTrove's existing through-hole array patent portfolio with new method and device claims. BioTrove employs a through-hole array technology for its Living Chip™ platform, a massively parallel liquid handling system of nanoliter samples for genomic, proteomic and high throughput screening and storage applications.

According to Dr. Colin J.H. Brenan, President and Chief Executive Officer of BioTrove, "BioTrove has greatly strengthened its competitive position in nanofluidic through-hole array technology with the purchase of the GCOR IP portfolio. We are poised to become the leader in nanofluidic technology for the life sciences."

About BioTrove

BioTrove, Inc. is a privately held, biotechnology company focused on leveraging revolutionary micro- and nano-scale engineering solutions to overcome current bottlenecks in pharmaceutical drug discovery and biotechnology. BioTrove has developed two innovative nanofluidic technologies - the Living Chip™ and Momentum™ - that enable the rapid processing of molecular information encoded in nanoliter reaction volumes. BioTrove offers integrated library storage and screening services based on the core technology as well as advanced instrumentation to partners.

For more information contact:

Dr. Colin Brenan
President and Chief Executive Officer
BioTrove, Inc.
info@biotrove.com
(781) 721-3615

Shannon Altimari
Feinstein Kean Healthcare
saltimari@fkhealth.com
(617) 577-8110